Press releases

8 Jan 2024

UCB announces European Commission approval of RYSTIGGO[®]▼ (rozanolixizumab) for the treatment of adults with generalized myasthenia gravis in Europe

27 Dec 2023

BIMZELX® (bimekizumab) Receives Approval in Japan for the Treatment of Psoriatic Arthritis, Non-radiographic Axial Spondyloarthritis and Ankylosing Spondylitis

4 Dec 2023

UCB announces European Commission approval of ZILBRYSQ[®]▼ (zilucoplan) for the treatment of adults with generalized Myasthenia Gravis

1 Dec 2023

UCB presents new data advancing patient-focused scientific leadership at American Epilepsy Society Annual Meeting

23 Nov 2023

Transparency notification Wellington

16 Nov 2023

‘Rheumacensus’ experts unite and call for essential psoriatic arthritis and axial spondyloarthritis care improvements

Press releases

Press releases

Search Press releases

UCB announces European Commission approval of RYSTIGGO[®]▼ (rozanolixizumab) for the treatment of adults with generalized myasthenia gravis in Europe

BIMZELX® (bimekizumab) Receives Approval in Japan for the Treatment of Psoriatic Arthritis, Non-radiographic Axial Spondyloarthritis and Ankylosing Spondylitis

UCB announces European Commission approval of ZILBRYSQ[®]▼ (zilucoplan) for the treatment of adults with generalized Myasthenia Gravis

UCB presents new data advancing patient-focused scientific leadership at American Epilepsy Society Annual Meeting

Transparency notification Wellington

‘Rheumacensus’ experts unite and call for essential psoriatic arthritis and axial spondyloarthritis care improvements

Choose a Country

Hypothesize That! Discover our new science podcast, where science meets conjecture and curiosity

Publications - A dedicated space where we share a collection of our scientific peer-reviewed...

Pipeline - Check out our clinical development pipeline spanning several therapy areas

At UCB, we imagine an HS-free world. And we’re taking steps to make it a reality. Download our...

WoCBA - Closing the gaps in research in the care of women of childbearing age with chronic diseases

Clinical studies – Click to find out more on our clinical studies

Integrated Annual Report 2025 - Direct access to our latest annual report

UCB Community Health Fund enters a new phase

UCBCares® - Discover what UCBCares® is about and the services they offer

BIMZELX[®]▼(bimekizumab) superior to SKYRIZI[®] (risankizumab) in BE BOLD: first head-to-head study...

Strong Execution Fueling Sustained Company Growth

KYGEVVI[®] (doxecitine and doxribtimine) recommended for approval in the European Union as treatment...

Strong Execution Fueling Sustained Company Growth

Innovation and Execution Power UCB’s Success

Download center – Click here to view a collection of useful documents

Press releases

Search Press releases

UCB announces European Commission approval of RYSTIGGO[®]▼ (rozanolixizumab) for the treatment of adults with generalized myasthenia gravis in Europe

BIMZELX® (bimekizumab) Receives Approval in Japan for the Treatment of Psoriatic Arthritis, Non-radiographic Axial Spondyloarthritis and Ankylosing Spondylitis

UCB announces European Commission approval of ZILBRYSQ[®]▼ (zilucoplan) for the treatment of adults with generalized Myasthenia Gravis

UCB presents new data advancing patient-focused scientific leadership at American Epilepsy Society Annual Meeting

Transparency notification Wellington

‘Rheumacensus’ experts unite and call for essential psoriatic arthritis and axial spondyloarthritis care improvements

Choose a Country